[{"orgOrder":0,"company":"Erkim","sponsor":"MEDICE Health Family","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"TURKEY","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Erkim \/ MEDICE Health Family","highestDevelopmentStatusID":"15","companyTruncated":"Erkim \/ MEDICE Health Family"},{"orgOrder":0,"company":"Erkim","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"TURKEY","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Erkim \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Erkim \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Erkim","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TURKEY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Erkim \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Erkim \/ Quoin Pharmaceuticals"},{"orgOrder":0,"company":"Erkim","sponsor":"Quoin Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"TURKEY","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"QRX003","moa":"Serine protease","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Erkim \/ Quoin Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Erkim \/ Quoin Pharmaceuticals"},{"orgOrder":0,"company":"Erkim","sponsor":"Polaris Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TURKEY","productType":"Enzyme","year":"2025","type":"Agreement","leadProduct":"Pegargiminase","moa":"||Arginine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Erkim \/ Polaris Group","highestDevelopmentStatusID":"9","companyTruncated":"Erkim \/ Polaris Group"}]

Find Clinical Drug Pipeline Developments & Deals by Erkim

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Under the agreement, Polaris will holds the rights for commercialization of ADI-PEG 20 (pegargiminase). It is being evaluated in late-satge for the treatment of malignant pleural mesothelioma

                          Product Name : ADI-PEG 20

                          Product Type : Enzyme

                          Upfront Cash : Undisclosed

                          April 15, 2025

                          Lead Product(s) : Pegargiminase,Cisplatin,Pemetrexed

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Polaris Group

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Under the agreement, Er-Kim partner with the MEDICE to commercialize the Vafseo (vadadustat). It is being indicated for the treatment of of symptomatic anaemia associated with CKD in adults.

                          Product Name : Vafseo

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 14, 2025

                          Lead Product(s) : Vadadustat

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved FDF

                          Sponsor : MEDICE Health Family

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Under the collaboration, Er-Kim Pharmaceuticals will commercialize Orladeyo (berotralstat), the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older, in Tur...

                          Product Name : Orladeyo

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 19, 2023

                          Lead Product(s) : Berotralstat HCl

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : BioCryst Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Under the terms of the revenue sharing agreement, ER-Kim gains exclusive rights to commercialize QRX003 in fifteen countries throughout the CEE. Quoin will be the exclusive supplier of QRX003 to ER-Kim.

                          Product Name : QRX003

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 02, 2022

                          Lead Product(s) : QRX003

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Preclinical

                          Sponsor : Quoin Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Under the terms of the revenue sharing agreement, which was initially announced earlier in February 2022, ER-Kim gains exclusive rights to commercialize QRX003 in six additional countries. Quoin will be the exclusive supplier of QRX003 to ER-Kim.

                          Product Name : QRX003

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 03, 2022

                          Lead Product(s) : QRX003

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Preclinical

                          Sponsor : Quoin Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank